glp-1 class drugs New Guidelines for Type 2 Diabetes in 2025 GLP-1 Safety Check - National
Description
The efficacy and safety of exenatide once weekly in patients with type 2 diabetes
34.5 per 100,000 person-years, HR 1.75, 95% CI 1.222.49) in a population-based study [107]
Turmeric Root Turmeric is truly a superstar in the herbal world
After an average of 25 months, the primary composite outcome of CV death, myocardial infarction, stroke, or hospitalization for unstable angina occurred in 13.4% of individuals in the lixisenatide group compared to 13.2% in the placebo group (hazard ratio [HR] 1.02
Results Seven trials (6609 participants) were included
These lifestyle modifications will help with both weight loss and diabetes in addition to GLP-1s
